Literature DB >> 7917903

Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs.

B G Siim1, G J Atwell, W R Wilson.   

Abstract

The cytotoxic potency of 4-alkylamino-5-nitroquinoline drugs in AA8 cell cultures is enhanced up to 60-fold under hypoxia, with wide variations in selectivity for hypoxic cells observed for different members of this series. This study uses three representative 5-nitroquinolines to examine whether these differences in hypoxia-selective cytotoxicity are cell line specific, and to explore quantitatively the oxygen dependence of the cytotoxicity and metabolism of these compounds. The parent compound 5NQ, its 5NQ, its 8-methyl analogue (8Me5NQ) and the 8-methylamino analogue (8NHMe-5NQ) each showed similar hypoxic selectivity (ratio of concentration x time for 90% kill for zero versus 20% oxygen of 13-18-, 30-69- and 1.2-1.4-fold respectively in the three cell lines tested (AA8 Chinese hamster ovary, EMT6/Ak mouse mammary tumour and FME human melanoma). The cytotoxicity and metabolism (covalent binding) of radiolabelled 8Me-5NQ was investigated in AA8 cultures over a range of oxygen tensions (0-95%). The oxygen tension in solution required for 50% inhibition of log cell kill or adduct formation observed under anoxia (C50) was 0.01 and 0.02% oxygen respectively, suggesting that bioreductive alkylation is the mechanism of 8Me-5NQ toxicity. The K-value (oxygen concentration for cytotoxic potency equal to the mean of the potencies at zero and infinite oxygen) was similar (0.02% oxygen). Calculations based on measured rate constants for formation of the nitroradical anion of 8Me-5NQ and rates of radical loss through disproportionation or reaction with oxygen, predict a K-value for 8Me-5NQ of 0.025% oxygen, in good agreement with the experimentally determined value. Modelling of cell killing expected by the combination of 8Me-5NQ plus radiation suggested that tumour cells at intermediate oxygen tensions (0.01-1%) will be partially resistant to this treatment, and would limit the use of these 5-nitroquinolines in combination with radiation, unless sufficient drug could be delivered to cause extensive killing in the anoxic compartment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917903      PMCID: PMC2033401          DOI: 10.1038/bjc.1994.357

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  38 in total

1.  Measurement of low levels of oxygen and their effect on respiration in cell suspensions maintained in an open system.

Authors:  R S Marshall; C J Koch; A M Rauth
Journal:  Radiat Res       Date:  1986-10       Impact factor: 2.841

2.  In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain.

Authors:  T R Chen
Journal:  Exp Cell Res       Date:  1977-02       Impact factor: 3.905

3.  A rapid-mixing comparison of the mechanisms of radiosensitization by oxygen and misonidazole in CHO cells.

Authors:  D W Whillans; J W Hunt
Journal:  Radiat Res       Date:  1982-04       Impact factor: 2.841

4.  Adriamycin: a possible indirect radiosensitizer of hypoxic tumor cells.

Authors:  R E Durand
Journal:  Radiology       Date:  1976-04       Impact factor: 11.105

Review 5.  Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies.

Authors:  J D Chapman
Journal:  Radiother Oncol       Date:  1991       Impact factor: 6.280

6.  Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771.

Authors:  W R Wilson; J W Moselen; S Cliffe; W A Denny; D C Ware
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-05-15       Impact factor: 7.038

7.  Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.

Authors:  C J Koch
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

8.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix.

Authors:  M Höckel; C Knoop; K Schlenger; B Vorndran; E Baussmann; M Mitze; P G Knapstein; P Vaupel
Journal:  Radiother Oncol       Date:  1993-01       Impact factor: 6.280

9.  5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine.

Authors:  W R Wilson; B G Siim; W A Denny; P L van Zijl; M L Taylor; D M Chambers; P B Roberts
Journal:  Radiat Res       Date:  1992-09       Impact factor: 2.841

Review 10.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

View more
  8 in total

1.  Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.

Authors:  Kevin O Hicks; Bronwyn G Siim; Jagdish K Jaiswal; Frederik B Pruijn; Annie M Fraser; Rita Patel; Alison Hogg; H D Sarath Liyanage; Mary Jo Dorie; J Martin Brown; William A Denny; Michael P Hay; William R Wilson
Journal:  Clin Cancer Res       Date:  2010-08-20       Impact factor: 12.531

Review 2.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

3.  Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.

Authors:  Jiechuang Su; Yongchuan Gu; Frederik B Pruijn; Jeff B Smaill; Adam V Patterson; Christopher P Guise; William R Wilson
Journal:  J Biol Chem       Date:  2013-11-06       Impact factor: 5.157

4.  A simple and inexpensive method to control oxygen concentrations within physiological and neoplastic ranges.

Authors:  P G Penketh; K Shyam; R P Baumann; E S Ratner; A C Sartorelli
Journal:  Anal Biochem       Date:  2015-09-08       Impact factor: 3.365

5.  Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.

Authors:  Cho Rong Hong; Sunali Y Mehta; H D Sarath Liyanage; Sarah P McManaway; Ho H Lee; Jagdish K Jaiswal; Gib Bogle; Moana Tercel; Frederik B Pruijn; William R Wilson; Kevin O Hicks
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-10       Impact factor: 3.333

Review 6.  Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.

Authors:  Annika Foehrenbacher; Timothy W Secomb; William R Wilson; Kevin O Hicks
Journal:  Front Oncol       Date:  2013-12-27       Impact factor: 6.244

7.  The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.

Authors:  Annika Foehrenbacher; Kashyap Patel; Maria R Abbattista; Chris P Guise; Timothy W Secomb; William R Wilson; Kevin O Hicks
Journal:  Front Oncol       Date:  2013-10-07       Impact factor: 6.244

8.  Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.

Authors:  B G Siim; P L van Zijl; J M Brown
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.